Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $7.20 Consensus Target Price from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $7.20.

PYXS has been the subject of a number of research reports. Guggenheim increased their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Royal Bank Of Canada decreased their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. HC Wainwright boosted their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th.

Pyxis Oncology Trading Up 3.3%

PYXS opened at $1.56 on Tuesday. The stock has a market capitalization of $97.13 million, a P/E ratio of -0.97 and a beta of 1.44. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.55. The firm’s fifty day simple moving average is $2.62 and its 200 day simple moving average is $2.43.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. On average, equities research analysts predict that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd acquired a new position in Pyxis Oncology during the second quarter valued at approximately $26,000. Avanza Fonder AB acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $31,000. XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the 2nd quarter valued at approximately $40,000. Velan Capital Investment Management LP bought a new position in shares of Pyxis Oncology in the second quarter valued at $44,000. Finally, Persistent Asset Partners Ltd acquired a new position in Pyxis Oncology during the third quarter worth $77,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.